Who are Tadalafil versus tamsulosin as MET's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tadalafil-versus-tamsulosin-as-met.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Tadalafil versus tamsulosin as MET — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tadalafil versus tamsulosin as MET (Tadalafil versus tamsulosin as MET) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PDE5 inhibitor (tadalafil) vs. alpha-1A adrenergic antagonist (tamsulosin). Area: Urology / Benign Prostatic Hyperplasia.

marketed PDE5 inhibitor (tadalafil) vs. alpha-1A adrenergic antagonist (tamsulosin) PDE5 (tadalafil) vs. alpha-1A adrenergic receptor (tamsulosin) Urology / Benign Prostatic Hyperplasia Small molecule Live · refreshed every 30 min

Target snapshot

Tadalafil versus tamsulosin as MET (Tadalafil versus tamsulosin as MET) — Beni-Suef University. Tadalafil is a phosphodiesterase-5 inhibitor that relaxes smooth muscle in the prostate and bladder, improving urinary flow; tamsulosin is an alpha-1A adrenergic antagonist that selectively blocks receptors in the prostate to reduce urinary obstruction.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Tadalafil versus tamsulosin as MET TARGET	Tadalafil versus tamsulosin as MET	Beni-Suef University	marketed	PDE5 inhibitor (tadalafil) vs. alpha-1A adrenergic antagonist (tamsulosin)	PDE5 (tadalafil) vs. alpha-1A adrenergic receptor (tamsulosin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PDE5 inhibitor (tadalafil) vs. alpha-1A adrenergic antagonist (tamsulosin) class)

Beni-Suef University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tadalafil versus tamsulosin as MET — Competitive Intelligence Brief. https://druglandscape.com/ci/tadalafil-versus-tamsulosin-as-met. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab